Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb 1;201(3):473-7.
doi: 10.1086/649901.

Immunological reactivity of blood from healthy humans to the rAls3p-N vaccine protein

Beverlie Baquir  1 , Lin Lin, Ashraf S Ibrahim, Yue Fu, Valentina Avanesian, Ang Tu, John Edwards Jr, Brad Spellberg
Affiliations

Immunological reactivity of blood from healthy humans to the rAls3p-N vaccine protein

Beverlie Baquir et al. J Infect Dis. .

Abstract

We determined reactivity of human blood to a vaccine based on the recombinant N-terminus of candidal Als3p (rAls3p-N) in preparation for future clinical trials. Healthy donor plasma had high immunoglobulin G titers (median, 1:51,200) and lower immunoglobulin A (median, 1:3,200) and immunoglobulin E (median, 1:128) titers to rAls3p-N by enzyme-linked immunosorbent assay. rAls3p-N stimulated interferon gamma (IFN-gamma) and interleukin (IL)-17, but not IL-4, from donor lymphocytes by enzyme-linked immunosorbent spot assay and IL-12 p70, IFN-gamma, IL-17, and IL-10 by cytometric bead array. Donors reacted to diverse immunodominant epitopes. Thus, facile humoral and cellular assays can monitor immune responses to the rAls3p-N vaccine in planned clinical trials.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest: B.S., A.S.I, Y.F., and J.E.E own equity in NovaDigm Therapeutics, which is developing vaccine technologies. NovaDigm Therapeutics provided no financial support for these studies.

Figures

Figure 1
Figure 1
Healthy human donors have preexisting immunity to the rAls3p-N vaccine protein. A, Serum samples from 13 donors were tested in immunoglobulin (Ig) G, IgG1, IgG2, IgG3, and IgG4 enzyme-linked immunosorbent assays to quantify rAls3p-N titers. Bars denote median titers. B, Peripheral blood mononuclear cells (PBMCs) from healthy human donors produce interferon (IFN)–γ and interleukin (IL)–17 in response to the rAls3p-N protein and to pre-germinated, heat-killed Candida albicans. Results from 14 donors are shown in both graphs. Spots from each well were normalized per 105 PBMCs. Bars denote median values. *P <.05 versus media; **P <.05 versus both rAls3p-N and media. C, Supernatants from 6 donor PBMCs were assayed for cytokines by Cytometric Bead Array. Bars denote median values. *P <.05 versus media control.
Figure 2
Figure 2
Immunodominant epitopes span the entire rAls3p-N sequence. Peripheral blood mononuclear cells (PBMCs) from 12 individual donors were cultured with individual 20-mer peptides, overlapping by 10 amino acids each, spanning the length of the rAls3p-N molecule. Each individual donor (Y axis) is plotted against the sequential 20-mer peptide numbers (X axis) which induced the highest number of interferon γ (IFN-γ) spots in the enzyme-linked immunosorbent spot assay for that donor’s PBMCs. Peptides inducing responses ≥95th percentile of responses (ie, ≥2 standard deviations above the mean response to all peptides) are plotted for each donor.
See this image and copyright information in PMC

References

    1. Spellberg B, Ibrahim AS, Lin L, et al. An antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity. J Infect Dis. 2008;197:957–971. - PMC - PubMed
    1. Spellberg B, Ibrahim AS, Yeaman M, et al. The anti-fungal rAls3p-N vaccine protects mice against the bacterium Staphylococcus aureus. Infect Immun. 2008;76:4574–4580. - PMC - PubMed
    1. Lin L, Ibrahim AS, Xu X, et al. Th1–Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathogens. in press. - PMC - PubMed
    1. Lin L, Ibrahim AS, Baquir B, Avanesian V, Fu Y, Spellberg B. Immunological surrogate marker of rAls3p-N vaccine-induced protection against Staphylococcus aureus. FEMS Immunol Med Microbiol. 2009;55(3):293–295. - PMC - PubMed
    1. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47:401–409. - PubMed

Publication types